Compile Data Set for Download or QSAR
Report error Found 38 Enz. Inhib. hit(s) with all data for entry = 10351
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529549(US11203586, Example 1)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529581(US11203586, Example 32)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529579(US11203586, Example 31)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529578(US11203586, Example 30)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529577(US11203586, Example 29)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529575(US11203586, Example 27)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529573(US11203586, Example 25)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529573(US11203586, Example 25)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529572(US11203586, Example 24)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529570(US11203586, Example 22)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529569(US11203586, Example 21)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529568(US11203586, Example 20)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529583((S)-1-(aziridin-1-ylsulfonyl)-N—((S)-1-(2-chl...)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529565(US11203586, Example 17)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529564(US11203586, Example 16)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529562(US11203586, Example 14)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529585((R)-1-(aziridin-1-ylsulfonyl)-N—((S)-1-(2-chl...)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529553(US11203586, Example 5)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529554(US11203586, Example 6)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529584(US11203586, Example 35)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529556(US11203586, Example 8)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM50503275(CHEMBL4447740 | US11203586, Example 10)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529560(US11203586, Example 12)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529561(US11203586, Example 13)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529563(US11203586, Example 15)
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529571(US11203586, Example 23)
Affinity DataIC50: 100nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529557(US11203586, Example 9)
Affinity DataIC50: 100nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529559(US11203586, Example 11)
Affinity DataIC50: 100nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529574(US11203586, Example 26)
Affinity DataIC50: 100nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529567(US11203586, Example 19)
Affinity DataIC50: 100nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529576(US11203586, Example 28)
Affinity DataIC50: 100nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529552(US11203586, Example 4)
Affinity DataIC50: 100nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529582(US11203586, Example 33)
Affinity DataIC50: 100nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529550(US11203586, Example 2)
Affinity DataIC50: 500nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529586(US11203586, Example 37)
Affinity DataIC50: 1.00E+3nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529566((S)-1-(aziridin-1-ylsulfonyl)-N—((R)-1-(2-chl...)
Affinity DataIC50: 1.00E+4nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529555(US11203586, Example 7)
Affinity DataIC50: 1.00E+4nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Chia Tai Tianqing Pharmaceutical Group

US Patent
LigandPNGBDBM529551((R)-2-(aziridine-1-sulfonylamino)-N—((R)-(2-c...)
Affinity DataIC50: 1.00E+4nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent